Inhalant abuse with inhalant-induced dementia
ICD-10 F18.17 is a billable code used to indicate a diagnosis of inhalant abuse with inhalant-induced dementia.
Inhalant abuse refers to the intentional inhalation of volatile substances to achieve psychoactive effects. This behavior can lead to significant cognitive impairment, known as inhalant-induced dementia, characterized by memory loss, impaired judgment, and difficulties in problem-solving. The substances commonly abused include glues, paints, solvents, and gases, which can cause both short-term intoxication and long-term neurological damage. The clinical presentation may include confusion, disorientation, and changes in personality, often resembling other forms of dementia. Diagnosis requires a thorough history of substance use, cognitive assessment, and exclusion of other potential causes of dementia. Treatment typically involves cessation of inhalant use, supportive care, and rehabilitation programs aimed at cognitive recovery and addressing underlying substance use disorders. Long-term follow-up is essential to monitor cognitive function and prevent relapse into substance abuse.
Detailed history of substance use, mental status examination, and cognitive assessments.
Patients presenting with cognitive decline and a history of inhalant use.
Consideration of comorbid mental health disorders and their impact on treatment.
Neurological evaluations, imaging studies, and cognitive testing results.
Patients with unexplained cognitive deficits and a history of inhalant abuse.
Differentiating between inhalant-induced dementia and other neurodegenerative conditions.
Used when assessing cognitive function in patients with inhalant abuse.
Document the purpose of testing and results.
Psychiatric evaluations may require additional documentation for mental health assessments.
The primary focus is on cessation of inhalant use, cognitive rehabilitation, and addressing any co-occurring mental health disorders.
